^
Association details:
| Biomarker: | TP53 R175H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Excerpt:
We also report three new patient cases with METex14 alterations in lung or histiocytic sarcoma tumors that showed durable response to two different MET-targeted therapies...Comprehensive genomic profiling demonstrated that the tumor harbored a METex14 alteration (c.2888-5_2944del62) as well as TP53 p.R175H and ZMYM3 c.3008-1G>A. The patient was not a candidate for surgical therapy, so systemic treatment options were investigated. After 4 months of treatment with crizotinib, the lesion decreased >60% in volume, deemed a partial response...
DOI:
10.1158/2159-8290.CD-15-0285
